Prostaglandin E Receptor EP4 expression, survival and pattern of recurrence in locally advanced NSCLC
- 1 November 2016
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 101, 88-91
Abstract
No abstract availableKeywords
Funding Information
- P.J. Aldridge Foundation (101BX000169, NCI P30 CA134274)
This publication has 25 references indexed in Scilit:
- Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung CancerPLOS ONE, 2012
- Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2Breast Cancer Research and Treatment, 2011
- COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancerBMC Cancer, 2010
- The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Identification of EP4 as a Potential Target for the Treatment of Castration-Resistant Prostate Cancer Using a Novel Xenograft ModelCancer Research, 2010
- Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cellsCancer Immunology, Immunotherapy, 2008
- Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203Journal of Clinical Oncology, 2008
- In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP4 receptor antagonistLife Sciences, 2008
- Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer MetastasisCancer Research, 2006
- Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and DocetaxelClinical Cancer Research, 2005